Lunit

Lunit develops medical AI software for cancer screening and precision oncology. Its products read clinical images, including mammograms, chest radiographs and pathology slides, and turn them into findings a radiologist or pathologist can act on, supporting detection at the screening end of the cancer pathway and treatment decisions at the other. Customers are hospitals, imaging centers and radiology departments, and biopharma companies that use the technology in clinical trials and companion diagnostics. The cancer screening suite includes Lunit INSIGHT MMG for 2D mammography, Lunit INSIGHT DBT for digital breast tomosynthesis and Lunit INSIGHT CXR for chest radiographs, alongside Risk Pathways for risk assessment, Scorecard for breast density, Analytics and Live for quality management and Patient Hub for mammography reporting. The precision oncology suite includes Lunit SCOPE IO for tumor microenvironment analysis, the Lunit SCOPE IHC Suite for quantifying immunohistochemistry markers such as HER2, and Lunit SCOPE GP for genotype prediction from pathology images. The company lists a substantial body of peer reviewed publications behind these products. Pricing is not published. Lunit's products are sold to institutions and to pharmaceutical partners under commercial agreements, and there is no plan list, price or self serve purchase on the site.